in vitro News and Research

RSS

Researchers create nanosurfaces to seal leg prosthetics against bacteria entry

In recent years, researchers have worked to develop more flexible, functional prosthetics for soldiers returning home from battlefields in Afghanistan or Iraq with missing arms or legs. But even new prosthetics have trouble keeping bacteria from entering the body through the space where the device has been implanted.

23 Mar 2011

Rxi's new RNAi preclinical data to be presented at Keystone conference

RXi Pharmaceuticals Corporation, a recognized leader in RNA interference based therapeutic discovery and development, today announced that new preclinical data using proprietary self-delivering RNAi compounds, including RXI-109, will be presented at the Keystone Symposia's Mechanism and Biology of Silencing conference being held March 20-25, 2011 in Monterey, California.

22 Mar 2011

China PharmaHub, University of California enter license agreement for stem cell universal donor blood product

China PharmaHub Corp., a biopharmaceutical acquisition and development company, today announced that it has signed a exclusive worldwide license agreement with the University of California, for worldwide rights to develop, commercialize and market a universal donor blood product derived from embryonic stem cells developed by UCSD Associate Professor of Medicine and Pediatrics Dr. Ewa Carrier.

21 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Roundup: Kan., Calif. budget cuts; Texas NICU costs; Katrina trial; Medco CalPERS contract 'dumped'

This list of programs cut in the California state budget includes a 10 percent reduction in what the state pays for Medi-Cal patients at all long-term care facilities $172.3 million and a 10 percent reduction in what the state pays to physicians who see people on Medi-Cal.

21 Mar 2011

Study on biodegradable tooth-binding micelles that inhibit Streptococcus mutans biofilm growth

Today, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher F. Cheni will hold an oral presentation on a research study titled "Biodegradable Tooth-binding Micelles Inhibit Streptococcus mutans (S. mutans) Biofilm Growth."

21 Mar 2011

EDMA endorses the campaign against excessive use of salt

EDMA, the European Diagnostic Manufacturers Association, fully endorses the 2011 World Salt Awareness Week theme “Salt and Men’s Health” as the latter reminds that more men than women die prematurely of cardiovascular diseases (CVD).

21 Mar 2011

Tocopherol derivatives as new dioxin receptor antagonists

When reactive oxygen species (ROS) hit the body, vitamin E helps to prevent damage to tissues and cells by acting as an antioxidant. The health benefits of vitamin E are numerous, and in fact, studies have found that people with higher levels of vitamin E in their system have a lower risk of heart disease and certain forms of cancer. A team led by Thomas Rosenau from the University of Natural Resources and Life Sciences in Vienna (Austria) now describe their synthesis of a series of modified vitamin E derivatives that show promise as dioxin receptor antagonists in the European Journal of Organic Chemistry.

18 Mar 2011

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.

From Quest Diagnostics 18 Mar 2011

Celera reports net revenue of $34.9 million for fourth quarter of 2010

Celera Corporation today reported net revenues of $34.9 million for the fourth quarter of 2010 that ended December 25, 2010, compared to $39.2 million for the prior year quarter.

18 Mar 2011

Ventana, CST enter license agreement for personalized cancer diagnostics

Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has granted Ventana Medical Systems, Inc., a worldwide non-exclusive license to CST patent rights and proprietary antibody reagents relating to the detection of epidermal growth factor receptor mutations for the field of tissue-based in vitro diagnostic testing.

From Cell Signaling Technology 16 Mar 2011

Omeros fourth quarter net loss increases to $7.2 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

15 Mar 2011

ExonHit receives CE mark approval for AclarusDx to diagnose AD

ExonHit Therapeutics announces today CE marking of AclarusDx, its blood-based test intended to help in the diagnosis of Alzheimer's disease. This gives AclarusDx the status of In Vitro Diagnostic.

15 Mar 2011

TESE surgical technique can help men with childhood cancer experience parenthood

A new study has shown that a surgical technique called microdissection testicular sperm extraction can effectively locate and extract viable sperm in more than one-third of adult male childhood cancer survivors who were previously considered sterile due to prior chemotherapy treatment.

15 Mar 2011

SAP may serve as effective nanomaterial to prevent prostate cancer spread

When prostate cancer stem cells were enclosed in self-assembling nanomaterials made of peptides, the SAP stopped cancer stem cell colony formation and also stopped the division of cancer cells in laboratory cultures.

11 Mar 2011

Fluidigm fourth quarter revenue increases to $10.4 million

Fluidigm Corporation today announced its financial results for the fourth quarter and full year ended December 31, 2010.

9 Mar 2011

Chemotherapy drugs also kill malaria parasite

A group of researchers from EPFL's Global Health Institute (GHI) and Inserm (Institut National de la Sant- et de la Recherche M-dicale, the French government agency for biomedical research) has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria. The discovery could quickly open up a whole new strategy for combating this deadly disease.

9 Mar 2011

New insight into malaria

A group of researchers from EPFL's Global Health Institute and Inserm has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria.

8 Mar 2011

Compugen reports positive results from CGEN-25068 in animal model to treat certain disease conditions

Compugen Ltd. announced today positive animal model results for CGEN-25068, a novel peptide predicted and selected in silico to block a specific protein-protein interaction known to play an important role in various immune-related disease conditions.

8 Mar 2011

hUCBs and MenSCs transplant may offer future therapeutic benefit for AD, stroke, ALS

Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.

8 Mar 2011